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ABSTRACT
Several studies have demonstrated that the delivery of type I, II, or III interferons (IFNs) by inoculation of a replication-defective
human adenovirus 5 (Ad5) vector expressing IFNs can effectively control foot-and-mouth disease (FMD) in cattle and swine dur-
ing experimental infections. However, relatively high doses are required to achieve protection. In this study, we identified the
functional properties of a porcine fusion protein, poIRF7/3(5D), as a biotherapeutic and enhancer of IFN activity against FMD
virus (FMDV).We showed that poIRF7/3(5D) is a potent inducer of type I IFNs, including alpha IFN (IFN-), IFN-, and IFN-
but not type III IFN (interleukin-28B), without inducing cytotoxicity. Expression of poIRF7/3(5D) significantly and steadily re-
duced FMDV titers by up to 6 log10 units in swine and bovine cell lines. Treatment with an IFN receptor inhibitor (B18R) com-
bined with an anti-IFN- antibody neutralized the antiviral activity in the supernatants of cells transduced with an Ad5 vector
expressing poIRF7/3(5D) [Ad5-poIRF7/3(5D)]. However, several transcripts with known antiviral function, including type I
IFNs, were still highly upregulated (range of increase, 8-fold to over 500-fold) by poIRF7/3(5D) in the presence of B18R. Further-
more, the sera of mice treated with Ad5-poIRF7/3(5D) showed antiviral activity that was associated with the induction of high
levels of IFN- and resulted in complete protection against FMDV challenge at 6, 24, or 48 h posttreatment. This study high-
lights for the first time the antiviral potential of Ad5-poIRF7/3(5D) in vitro and in vivo against FMDV.
IMPORTANCE
FMD remains one of the most devastating diseases that affect livestock worldwide. Effective vaccine formulations are available
but are serotype specific and require approximately 7 days before they are able to elicit protective immunity. We have shown that
vector-delivered IFN is an option to protect animals against many FMDV serotypes as soon as 24 h and for about 4 days postad-
ministration. Here we demonstrate that delivery of a constitutively active transcription factor that induces the production of
endogenous IFNs and potentially other antiviral genes is a viable strategy to protect against FMD.
Foot-and-mouth disease (FMD) is one of the most contagiousviral diseases that affect cloven-hoofed livestock worldwide.
The disease is enzootic in many regions of Africa, South America,
and Asia, causing enormous economic and social impacts (1, 2).
The causative agent, FMD virus (FMDV), is a nonenveloped virus
that belongs to the Picornaviridae family (1, 3, 4). FMDV is an
antigenically variable virus comprising seven serotypes and mul-
tiple subtypes. Serotypes A, O, and C were first isolated in Europe
and occur worldwide, while serotypes SAT-1 to SAT-3 and Asia-1
have traditionally been restricted to Africa and Asia, respectively
(1, 4, 5).
Infection of animals with FMDV results in rapid replication,
spread, and shedding of large amounts of virus, resulting in high
morbidity. Therefore, in case of an outbreak, FMD is controlled by
restriction of animal movement, slaughter of in-contact suscepti-
ble animals, and in some instances, vaccination with an inacti-
vated vaccine followed by slaughter. Although in some countries
where the disease is enzootic preventive vaccination is commonly
used (1), FMD-free countries tend to avoid vaccination due to the
more restrictive trading policies imposed by theWorld Organiza-
tion for Animal Health (OIE) (1). The current inactivated whole-
virus vaccine is effective, but a number of limitations, such as
difficulty in distinguishing infected from vaccinated animals
(DIVA) and the requirement for an expensive high-containment
facility for vaccine production, have led investigators to develop
alternative vaccine approaches (2, 6, 7). Although vaccination is
largely utilized worldwide to protect against FMD in countries
where it is enzootic, current vaccines do not always prevent infec-
tion but rather limit or block clinical signs and require at least 5 to
7 days to elicit a protective immune response, which results in
some animals becoming long-term carriers. Therefore, in case of
FMD outbreaks in disease-free countries, it is necessary to limit
disease spread and thus potentially reduce the number of animals
that have to be slaughtered by inducing rapid protection prior to
the development of vaccine-induced adaptive immunity.
Biotherapeutics represent an option to induce very early pro-
tection against FMDV infection (8). The interferon (IFN) re-
sponse is one of the first antiviral mechanisms naturally induced
in an infected host cell (9–11). IFNs are produced upon viral in-
fection andplay a crucial role in early innate immunity aswell as in
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subsequent adaptive immunity (12). The expression of type I IFN
is regulated by the activation of transcription factors, such as
members of the nuclear factor kappa B (NF-B) family (13), ac-
tivating transcription factor 2 (ATF-2)/c-Jun complex (14), inter-
feron regulatory factor 7 (IRF7) (15), and IRF3 (11), that bind to
specific sequences present at IFN promoter regions. IFN tran-
scription, followed by translation, secretion, and binding to spe-
cific receptors, triggers the induction of IFN-stimulated genes
(ISGs), which code for antiviral products that affect viruses at
different stages of their replication cycle, and different viruses are
susceptible to different ISG products (10, 16).
FMDV has developed several mechanisms to evade the host
immune response, including inhibition of cap-dependent host
translation; inhibition of IFN expression and/or IFN signaling,
presumably by virus-dependent degradation of NF-B; suppres-
sion of IRF3 and IRF7 activation; and deubiquitination of retinoic
acid-inducible gene I (RIG-I), TANK-binding kinase 1 (TBK1), tu-
mornecrosis factor (TNF) receptor-associated factor3 (TRAF3), and
TRAF6 (17–23). However, IFN proteins are still detected in the
serum and tissues of animals infected with FMDV, suggesting that
inhibition of translation induced by the virus might be temporal
and tissue or even cell specific (24). Animals that overexpress IFN,
delivered by inoculation of a replication-defective human adeno-
virus type 5-based vector (Ad5) expressing IFNs, are protected
against the clinical manifestations of disease and in some cases are
protected from primary infection in a dose-dependent manner
(25–28), suggesting that the strength, timing, and location of vi-
rus-host interactions are determinants critical to the outcome of
the disease. In any case, high doses of Ad5 expressing IFNs (Ad5-
IFNs) are required to achieve protection, resulting in an expensive
approach to control FMD; therefore, there is a need to enhance the
potency of this approach.
A construct, IRF7/3(5D), prepared using human sequences
was previously described (29) and contains 246 amino acids from
IRF7 (the DNA binding and constitutive activation domains) and
295 amino acids from IRF3(5D) (the transactivation and signal
response domains). Expression of this construct in cultured hu-
man cells induced the activation of IFN promoters in vitro (29).
Adjuvant properties of plasmids expressing IRF3(5D) or IRF7/
3(5D) have also been described in mice, but IFN expression was
not detected after intramuscular injection, presumably as a con-
sequence of the low efficacy of plasmid-derived gene transfer in
muscle tissue (30). Here, we describe the functional characteriza-
tion of a constitutively active porcine IRF7/3(5D) [poIRF7/
3(5D)] synthetic construct as an antiviral against FMDV. We
found that this fusion protein is a potent inducer of several type I
IFNs (but not type III IFNs) in cells from several species. Expres-
sion of poIRF7/3(5D) enhances the antiviral activity of an Ad5
vector expressing porcine beta IFN (Ad5–poIFN-) against
FMDV. Furthermore, mice inoculated with an Ad5 vector ex-
pressing poIRF7/3(5D) [Ad5-poIRF7/3(5D)] developed no
viremia after FMDV serotype A24 challenge, and their sera had
high levels of antiviral activity correlating with increased systemic
levels of murine IFN-/ (muIFN-/). This antiviral strategy
can contribute to the development of improved biotherapeutics to
control FMDV infection in animals.
MATERIALS AND METHODS
Cell and reagents. Swine kidney (SK6 and IBRS-2) cells were obtained
from the ForeignAnimalDiseaseDiagnostic Laboratory (APHIS) at Plum
Island Animal Disease Center (PIADC), Greenport, NY. Madin-Darby
bovine kidney (MDBK; ATCC CCL-22), baby hamster kidney (BHK-21,
clone 13, ATCC CCL-10), and mouse L929 (ATCC CCL-1) cells were
purchased from the American Type Culture Collection (ATCC; Manas-
sas, VA) and were used for plasmid transfection or Ad5 vector transduc-
tion. Human 293 cells (ATCC CRL-1573) were also purchased from
ATCC and were used to propagate recombinant Ad5 vectors (31). Mouse
embryonic fibroblasts (MEFs) were propagated from original clones
kindly provided by David E. Levy (New York University) (26). Cells were
cultured under standard tissue culture conditions andmaintained inmin-
imal essential medium (MEM) containing 10% fetal bovine serum (FBS)
supplemented with 1% antibiotics and nonessential amino acids. Ten
percent tryptose phosphate broth was included in the medium for
BHK-21 cells.
The inhibitor B18R (eBioscience, San Jose, CA) was used to block IFN
type I receptor signaling. Prior to transfection or infection, cells were
incubated for 1 h at room temperature in complete medium containing
the inhibitor B18R at a concentration of 200 ng/ml. The inhibitor B18R
was maintained in the medium during transfection and replenished after
viral infection. Anti-pig IFN- (clone K9) antibody (Ab; PBL Interferon
Source, Piscataway, NJ) was used to neutralize the IFN- activity present
in the supernatants (3 g of antibody/ml of supernatant) of treated cells.
In some transfections, poly(I·C) (InvivoGen, San Diego, CA) was used as
an inducer of IFN expression at the concentrations specified below.
Viral infections. A laboratory-adapted vesicular stomatitis virus
(VSV) serotype Indiana isolate was kindly provided by Judith Ball (Texas
A&M University). A VSV serotype New Jersey field strain (95COB) and
FMDV serotype A12 were generated from full-length-virus infectious
clones (32). FMDVA24,whichwas isolated from the field andpassed once
in BHK-21 cells, was used formouse experiments. All experimental infec-
tions using VSV serotype New Jersey or FMDV were conducted at the
USDA-ARS Plum Island Animal Disease Center under biosafety level 3
agricultural hazard (BSL-3Ag) conditions. Infections with VSV serotype
Indiana were performed at Texas A&M University under BSL-2 condi-
tions.
Cells were infected at the times posttransfection specified below or
transduced with Ad5 at the multiplicities of infection (MOIs) indicated
below. In all cases, FMDV or VSV was adsorbed for 1 h at 37°C. For
FMDV, unabsorbed virus was removed by washing the cells with 150mM
NaCl–20mMmorpholineethanesulfonic acid (MES; pH 6.0). Incubation
continued for 24 h, unless otherwise specified. Virus was released by one
freeze-thaw cycle. Viral titers were determined by a standard 50% tissue
culture infective dose (TCID50) method using IBRS-2 cells, and results
were expressed as the log10 number of TCID50/ml. Viral titers in FMDV-
infected mouse serum were determined by plaque assay, using standard
procedures (33), and expressed as the number of PFU/ml of serum.
Cell toxicity assay. Cell toxicity after transfection or transduction
of plasmids or Ad5 vectors expressing poIRF7/3(5D) was determined
by using a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)
carbonyl]-2H-tetrazolium hydroxide (XTT)-based in vitro toxicology
assay kit (Sigma, St. Louis,MO) following themanufacturer’s recommen-
dations. The optical density at 450 nm was read, and the optical density
was filtered at 650 nm after 4 h of incubation.Microscopic examination of
cell morphology in the monolayer after transfection/transduction was
also used as an indicator of cell toxicity.
Plasmid construction. Partial DNA sequences of porcine IRF7
(GenBank accession numberAB287430, nucleotides 212 to 964) and IRF3
(GenBank accession number AB116563.1, nucleotides 400 to 1260) were
used to synthesize the poIRF7/3(5D) fusion construct. This fusion con-
struct was then cloned at the XbaI/EcoRV sites of the pcDNA 3.1 zeo
vector (Invitrogen, Carlsbad, CA). A plasmid expressing the green fluo-
rescent protein (GFP) in the pcDNA 3.1 zeo background (pGFP) was
kindly provided by Michael Golding (Texas A&M University) and was
used as a control.
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Ad5 vector construction. The pcDNA 3.1 zeo poIRF7/3(5D) con-
struct was digested with ClaI and XbaI, and the resulting DNA fragment
was ligated into a pAd5-Blue vector (34) that had been digested with the
same enzymes to create recombinant Ad5-poIRF7/3(5D). Replication-
defective human Ad5 expressing poIRF7/3(5D) was produced by trans-
fection of 293 cells with the PacI-linearized recombinant pAd5-poIRF7/
3(5D). Viruses were isolated, propagated, and purified by CsCl gradient
centrifugation (34). The Ad5-Blue and Ad5–poIFN- vectors were con-
structed previously (26, 35).
Analysis of mRNA expression by RT-qPCR. Total RNA was isolated
from cell lysates using a commercially available extraction kit (Qiagen,
Valencia, CA). Two hundred to 1,000 ng of RNA was used to synthesize
cDNA using random hexamers with qScript kit mix (Quanta Biosciences,
Gaithersburg, MD) according to the manufacturer’s instructions. Copied
DNA was diluted 10-fold and used as the template for quantitative
(qPCR) with PerfeCTa SYBR green FastMix and carboxy-X-rhodamine
(Quanta Biosciences, Gaithersburg,MD). Sampleswere run in anApplied
Biosystems 7500 or StepOne real-time PCR system (Applied Biosystems,
Carlsbad, CA).
The expression of the genes of interest was normalized using GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) and -actin. Relative
quantificationwas performed for IRF7 and a panel of previously described
ISGs (10, 27). Standard curves were run to standardize a SYBR-green
based PCR array of the subtypes of porcine type I IFN. Sequences for
detecting subtypes of porcine type I IFNs (IFN-, -, -, -ε, -, and -)
were published previously (36–39).
Real-time qPCR (RT-qPCR) analysis was performed following the
guidelines for the minimum information for publication of quantitative
real-time PCR experiments (40). Data were analyzed using the compara-
tive threshold cycle (		CT) method (41).
IFN bioassay. The antiviral activity induced by IFN expression was
tested with a VSV infection inhibition assay as previously described (20).
Supernatants from cell cultures that had previously been transduced with
Ad5 vectors were filtered through Centricon 100 columns (Millipore, Bil-
lerica, MA) to remove adenovirus particles.
Sampleswere diluted 2-fold and incubated on IBRS-2 cells for approx-
imately 24 h. Supernatantswere then removed and cells were infectedwith
VSV serotype New Jersey (MOI 
 2). Twenty-four or 48 h later, the
cytopathic effect (CPE) was determined bymicroscopic examination, fol-
lowed by staining with 1% crystal violet. Antiviral activity (the IFN con-
centration in units/ml) was expressed as the reciprocal of the highest
dilution of supernatant able to suppress a VSV-induced cytopathic effect
in 50% of the assayed wells.
The antiviral activity in serum samples frommice inoculated with the
Ad5 vectors was tested on L929 cells as previously described (42). Briefly,
2-fold dilutions of serum samples were applied to confluent monolayers
of L929 cells. At 24 h, the cells were infected with VSV (MOI 
 20),
followed by 48 to 72 h of incubation at 37°C. CPEs were scored by micro-
scopic examination, followed by staining with 1% crystal violet.
Murine IFN ELISA. Serum samples from mice infected with Ad5-
poIRF7/3(5D) or the Ad5-Blue control vector were tested for the presence
of muIFN- andmuIFN- using VeriKine mouse enzyme-linked immu-
nosorbent assays (ELISAs; PBL Interferon Source, Piscataway, NJ) per the
manufacturer’s directions. The absorbance at 450 nmwasmeasured in an
ELISA plate reader (VersaMax; Molecular Devices, Sunnyvale, CA). Cy-
tokine concentrations were calculated on the basis of the optical densities
obtained with standard curves.
Mouse challenge studies. All animal work was conducted in compli-
ance with the AnimalWelfare Act (AWA), the 2011Guide for the Care and
Use of Laboratory Animals (43), the 2002 PHS Policy for theHumaneCare
and Use of Laboratory Animals, and U.S. Government Principles for Uti-
lization and Care of Vertebrates Animal Used in Testing, Research and
Training (44), as well as a specific animal protocol reviewed and approved
by the Institutional Animal Care andUseCommittee (IACUC) of PIADC.
Six- to 7-week-old female C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and acclimated for 1 week. In the
first experiment, two groups of five mice each were inoculated with Ad5-
poIRF7/3(5D) (3  107 or 3  108 PFU/mouse) or Ad5-Blue (3  108
PFU/mouse) subcutaneously (s.c.) in the dorsal flank. One day after Ad5
treatment, serum samples were collected for testing by the IFN ELISAs
and determination of total antiviral activity and themicewere euthanized.
In the second experiment, groups of fivemicewere inoculated s.c. with
3 108 PFU/mouse of Ad5-poIRF7/3(5D) or Ad5-Blue. A control group
was inoculated with phosphate-buffered saline (PBS). At 6, 24, or 48 h
after Ad5 treatment, mice were infected s.c. in the right rear footpad with
105 PFU of FMDV A24 in 50 l of PBS as previously described (45).
Animals weremonitored for 7 days, and blood was collected at 1, 3, 5, and
7 days postchallenge. Viremiawas determined by plaque assay onBHK-21
cells (33).
Similarly, in a third experiment, groups of five mice were inoculated
s.c. with PBS, Ad5-poIRF7/3(5D) (3 107 PFU/mouse), Ad5-Blue (3
107 PFU/mouse), or combinations of these treatmentswith 100 IUofmuIFN-
[(Ad5-poIRF7/3(5D) at 3  107 PFU/mouse plus 100 IU muIFN-, Ad5-
poIRF7/3(5D) at 3 106 PFU/mouse plus 100 IUmuIFN-, Ad5-Blue at
3  107 PFU/mouse plus 100 IU muIFN-, Ad5-Blue at 3  106 PFU/
mouse plus 100 IU muIFN-, or 100 IU muIFN-]. Ad5 inoculations
were performed 48 h prior to FMDV challenge, while recombinant
muIFN- was applied 24 h before FMDV challenge. Two days after Ad5
treatment (or 24 h after IFN treatment),micewere infected s.c. in the right
rear footpad with 105 PFU of FMDV A24. Animals were monitored for 7
days, and blood was collected at 1, 3, 5, and 7 days postchallenge. Viremia
was determined by plaque assay on BHK-21 cells (33).
Statistics and data analysis. Treatment differences were determined
using Student’s t test, Dunnett’s method, or the Wilcoxon rank sum test,
as indicated in the figure legends. Representative results of three indepen-
dent replicates are shown for all experiments except the mouse experi-
ments. Statistical analyses were performed using JMP software, version
8.0.2. Values are expressed as mean standard error or the mean (SEM),
and statistical significance is indicated in the figure legends.
RESULTS
poIRF7/3(5D) induces high levels of ISG expression. The IRF7
transcription factor shares structural features with IRF3 and in-
cludes a conservedDNAbinding domain (DBD) and a serine-rich
C-terminal region that is the target of virus-inducible phosphor-
ylation (46). Here, using domains analogous to human IRF7/3A,
we generated a chimeric construct of porcine IRF7 and IRF3,
poIRF7/3(5D). The construct contains the DBD and constitutive
activation domain (CAD) from porcine IRF7 but lacks the inhib-
itory domain (ID) (Fig. 1A). It also has the proline-rich domain
(Pro), transactivation domain (TAD), and signal response do-
main (SRD) from porcine IRF3. Analogous to the human con-
struct described previously (29), poIRF7/3(5D) contains muta-
tions at 5 amino acids in the C-terminal IRF3 domain that mimic
phosphorylation and therefore result in constitutive activation
(Fig. 1A).
Swine cells were transfected with the plasmid expressing the
fusion protein. Since the proapoptotic and cytotoxic effects of a
human IRF7/3(5D) construct have been previously described (29,
47), we evaluated the possible effects resulting from the overex-
pression poIRF7/3(5D) in swine cells. No cytotoxic effects of
poIRF7/3(5D) were detected when 25 to 100 ng of plasmid was
transfected in 2.5  105 cultured porcine cells (Fig. 1B). At a
higher concentration, i.e., 500 ng, a significant increase in cyto-
toxicity was observed (P 0.05).
Expression of poIRF7/3(5D) was analyzed by RT-qPCR using
primers and probes that detected IRF7 and IRF3 transcribed re-
gions. An IRF7 primer set detected both poIRF7/3(5D)-derived
Ramírez-Carvajal et al.
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and cellular IRF7 mRNAs. However, two sets of primers were
required to detect either plasmid-derived IRF3 (IRF3) or cellular
IRF3 (endogenous IRF3 [eIRF3]) transcripts. Total IRF7 and spe-
cific IRF3 transcribed from the poIRF7/3(5D) plasmid were sig-
nificantly upregulated (40-fold and 10-fold, respectively) in
cells transfected with the poIRF7/3(5D) plasmid compared to the
levels of regulation for the control groups of mock- or pGFP-
transfected cells (P  0.05) (Fig. 1C). Basal levels of IRF7 were
detected in mock- or pGFP-transfected cells, similar to the find-
ings for endogenous IRF3, whose levels also remained unchanged
in the poIRF7/3(5D)-transfected cells.
To determine if the overexpression of poIRF7/3(5D) was
able to induce changes in host gene profiles, three known ISGs,
2=,5=-oligoadenylate synthetase (OAS1), IFN-stimulated gene 54
(ISG54), andmyxovirus resistance 1 (Mx1), as well as IFN-, were
analyzed byRT-qPCR.While little or no inductionwas detected in
SK6 cells mock treated or transfected with pGFP, significant up-
regulation was detected in cells transfected with 25 ng of the
poIRF7/3(5D) fusion protein (Fig. 1D). Levels of induction vary-
ing from 100- to 250-fold were detected for all analyzed genes,
indicating that the fusion poIRF7/3(5D) protein was active.
poIRF7/3(5D) expressed in porcine cells has antiviral prop-
erties against FMDV and VSV. To test the biological functions of
the fusion protein poIRF7/3(5D) in the context of a viral infec-
tion, SK6 cells were mock transfected or transfected with 25 ng of
poIRF7/3(5D) or pGFP and later infected with either FMDV or
VSV. A striking reduction (5 to 6 log10 units) in the yield of FMDV
(Fig. 2A) orVSV (Fig. 2B) (P 0.0001 in all cases) was observed in
cells transfected with poIRF7/3(5D), while no effect was detected
in cells transfected with the control pGFP. Antiviral activity was
consistently detected only in supernatants from poIRF7/3(5D)-
transfected cells, and this activity was greatly decreased, but not
completely neutralized, when cells were treated with an anti-
poIFN- antibody (Table 1).
Antiviral activityagainstFMDVandVSVwasalsoevaluated in the
supernatants of IBRS-2 cells transfectedwith plasmids expressing the
poIRF7/3(5D) construct (Fig. 2C and D). Similar to the findings for
SK6 cells, there was a substantial reduction of viral titers (FMDVand
VSV) varying from 4 to 6 log10 units after transfection with plasmids
expressing poIRF7/3(5D), with no inhibition being detected in the
pGFP-transfectedcells.However, significantly less antiviral activity (6
times less) was detected in the supernatants of transfected IBRS-2
cells than in thoseof SK6cells (Table 1).Mostof thedetectedantiviral
activity was neutralized by addition of an anti-porcine IFN- anti-
body, suggesting that poIRF7/3(5D)mainly induces this type of IFN
in swine cells (Table 1).
poIRF7/3(5D) steadily reduces viral yield and enhances the
activity of Ad5–poIFN-. To determine if poIRF7/3(5D) could
FIG 1 Expression of poIRF3/7(5D) induces the expression of IFN and ISGmRNAs. (A) Schematics of porcine fusion [poIRF7/3(5D)] and parental [poIRF7 and
poIRF3(5D)] proteins used in this work. Asterisks represent 5 phosphomimetic amino acid substitutions (5D) at the C terminus of the IRF3 DNA binding
domain (DBD), proline-rich domain (Pro), transactivation domain (TAD), signal response domain (SRD), constitutive activation domain (CAD), and inhib-
itory domain (ID). aa, amino acids. (B) Cytotoxicity assays (XTT) on IBRS-2 cells 24 h after transfection with 25 to 500 ng of plasmid poIRF7/3(5D) or pGFP.
OD, optical density; Media, transfection of medium alone. (C) Expression of plasmid-derived IRF3/IRF7 or endogenous IRF3 (eIRF3) mRNAwas measured by
RT-qPCR in SK6 cells at 24 h posttransfection with plasmids poIRF7/3(5D) and pGFP.Mock transfection was used as a control. (D) Expression of OAS1, ISG54,
Mx1, or IFN-mRNA was measured by RT-qPCR in SK6 cells at 24 h after plasmid or mock transfection. Statistical analyses were performed using Dunnett’s
method (*, P 0.05) for panel B and the Wilcoxon rank sum test (*, P 0.05) for panels C and D.
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induce a sustained reduction of viral titers, IBRS-2 cells were
transfected with poIRF7/3(5D) and infected with FMDV A12 at
different times posttransfection.Nodifferences in viral yieldswere
detected earlier than 6 h posttransfection (hpt) with poIRF7/
3(5D) or pGFP or after mock transfection (Fig. 3A). However, by
24 hpt, a 3-log10-unit reduction in virus yieldwas detected andwas
sustained for up to 120 h only in the cells transfected with poIRF7/
3(5D).
In order to deliver poIRF7/3(5D) more efficiently, we cloned
its coding sequence into a replication-defective humanAd5 vector
(Ad5-Blue) previously developed at PIADC (34). Infection of
IBRS-2 cells with Ad5-poIRF7/3(5D) at anMOI of 2 resulted in an
approximately 5-log10-unit reduction in the number of FMDV
TCID50/ml (Table 2). Addition of IFN-neutralizing reagents (the
inhibitor B18R and anti-IFN-) neutralized most of the antiviral
activity, although some residual activity (1 log10 unit) was still
detected (Table 2).
Next, we evaluatedwhether Ad5-poIRF7/3(5D) could enhance
Ad5–poIFN- antiviral activity (28). SK6 cells were infected with
Ad5-poIRF7/3(5D) or combinations of Ad5–poIFN- and Ad5-
poIRF7/3(5D) or Ad5-Blue (empty vector) at 24 h prior to FMDV
challenge. A reduction of approximately 3 log10 units was detected
when cells were infected with Ad5-poIRF7/3(5D) at an MOI of
0.2. Interestingly, a dose-dependent decrease in viral yield of 2 to
3.5 log10 units compared to the viral yield with mock treatment
was observed when cells were coinfected with Ad5-poIRF7/3(5D)
atMOIs of 0.02, 0.1, and 0.2 combinedwith very small amounts of
Ad5–poIFN- (MOI
 10e4) (Fig. 3B). Combinations of Ad5-
poIRF7/3(5D) (MOI
 0.2) and Ad5–poIFN- (MOI
 10e4)
resulted in a significant reduction in virus titer of 2 log10
units (P  0.01) relative to that for cells treated with our con-
trol vector (Ad5-Blue) combined with Ad5–poIFN- at similar
FIG 2 poIRF7/3(5D) has significant antiviral activity against FMDV andVSV in porcine cell lines. SK6 (A and B) or IBRS-2 (C andD) cells were transfected with
25 ng of plasmid poIRF7/3(5D) or pGFP or mock transfected with medium alone. At 24 h posttransfection, the cells were infected with FMDV A12 or VSV
Indiana at anMOI of 0.1. Viral titers were determined by the TCID50 method at 24 h postinfection. Statistical analysis was performed using Student’s t test. ***,
P 0.001.
TABLE 1 Antiviral activity in the supernatants of porcine SK6 and
IBRS-2 cells after transfection with poIRF7/3(5D)a
Treatment Neutralizationb
Mean SEM IFN concn
(U/ml)
SK6 cells IBRS-2 cells
poIRF7/3(5D) 135.9 39.8 22.8 10.8
poIRF7/3(5D) Anti-IFN- 10.5 4.4 1.6 0.6
pGFP 1 0.0 1 0.0
pGFP Anti-IFN- 1 0.0 1 0.0
Mock 1 0.0 1 0.0
Mock Anti-IFN- 1 0.0 1 0.0
a An antiviral activity bioassay was performed in supernatants of SK6 or IBRS-2 cells
collected at 24 h posttransfection of 25 ng of plasmid DNA.
b In some supernatants, a neutralizing mouse anti-porcine IFN- antibody was added
to the cell supernatants prior to testing of VSV antiviral activity.
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MOIs. At the highest MOI used (0.2), Ad5-Blue did not signif-
icantly contribute to the reduction in virus titer induced by
Ad5–poIFN- (P  0.1). These results suggest that treatment
with Ad5-poIRF7/3(5D) enhances the antiviral activity of
Ad5–poIFN- against FMDV.
poIRF7/3(5D) induces antiviral responses in vitro in species
other than swine. Since IRF family members share some homol-
ogy, we studied the effect of poIRF7/3(5D) expression in vitro
across several species. The phylogenetic relationships among sev-
eral IRF3 protein sequences from some species available in public
databases were deduced by maximum likelihood (ML) analysis
(Fig. 4A) and verified by Bayesian inference. We confirmed that
the IRF3 sequences of species from more closely related taxo-
nomic groups, such as bovine, swine, and sheep, form a mono-
phyletic group, while those of primates, carnivores, and rodents
are more distantly related.
Interestingly, poIRF7/3(5D) induced a functional antiviral re-
sponse in vitro in cell lines from several species, including MDBK
(bovine), BHK-21 (hamster), or L929 (mouse) (Fig. 4). After in-
fection with Ad5 poIRF7/3(5D) or transfection with poIRF7/
3(5D) and subsequent challenge with FMDV or VSV, these cell
lines exhibited a drastic reduction in viral yield compared with
FIG 3 poIRF7/3(5D) induces sustained antiviral activity and potentiates the effects of Ad5–IFN-. (A) IBRS-2 cells were transfected with 25 ng of plasmid
poIRF7/3(5D) or pGFP or mock transfected. At the specified times posttransfection, cells were infected with FMDV A12 at an MOI of 1. At 24 h postinfection,
supernatants were collected for viral titration by the TCID50method. (B) SK6 cells were coinfected with Ad5–poIFN- (MOI
 10e4) and Ad5-poIRF7/3(5D)
at three different MOIs (0.2, 0.1, or 0.02), with Ad5–poIFN- (MOI 
 10e4) plus Ad5-Blue (MOI 
 0.2) or medium alone, or with Ad5-poIRF7/3(5D)
(MOI
 0.2). At 24 h, cells were challenged with FMDV at an MOI of 0.1 for 24 h, followed by determination of viral titers by the TCID50 method. Statistical
analysis was performed using Student’s t test. **, P 0.01.
TABLE 2 Antiviral activity induced by Ad5-poIRF7/3(5D)a
Treatment
Mean SEM log no. of TCID50/ml
B18R and anti-IFN-
negative
B18R and anti-IFN-
positive
Ad5-poIRF7/3(5D) 0.1 0.0 4.1 0.4
Medium 5.5 0.0 6.3 0.0
Ad5-Blue 5.1 0.4 5.4 0.4
a FMDV titers (log TCID50/ml) recovered from the supernatants of IBRS-2 cells 24 h
after infection with Ad5-poIRF7/3(5D) in the presence or absence of IFN-neutralizing
agents (B18R and anti-porcine IFN- antibody).
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that from mock-treated cells. The antiviral effect in mouse L929
cells (Fig. 4B) or MEFs (not shown) was less than that in porcine
(Fig. 2A to D) and bovine (Fig. 4C) cells. Consistent with our
previous data (42), transduction with Ad5–poIFN- did not pro-
tect murine cell lines from FMDV infection (Fig. 4B). The reduc-
tion in the FMDV yield in BHK-21 cells treated with the fusion
protein (Fig. 4D) was similar to the effect observed in SK6 cells
(Fig. 3A), but BHK-21 cells did not develop an antiviral response
after poly(I·C) stimulation.
Characterization of the antiviral response induced by
poIRF7/3(5D) in swine cells. The antiviral activity elicited by
transfection of the plasmid expressing poIRF7/3(5D) in SK6 or
IBRS-2 cells was not fully neutralized by addition of an anti-IFN-
antibody (Table 1). To determine whether the residual antiviral
activity could be attributed to the expression of other subtypes of
porcine type I IFN, we quantitated the relative transcript levels of
the IFN type I subtypes (IFN-, -, -, -ε, -, -) in cells treated
with the Ad5-poIRF7/3(5D). Infection with Ad5-poIRF7/3(5D)
induced expression of IFN-, -, and - in IBRS-2 cells (Fig. 5)
and SK6 cells (data not shown). However, IFN-, -ε, or -mRNA
or interleukin-28B (IL-28B; IFN-3) mRNA was not upregulated
in any of these two cell lines.
We also questioned if an antiviral effect independent of type I
IFNs might be involved in the strong antiviral response of IBRS-2
cells even when these cells showed less of an ability to induce
antiviral responses than SK6 cells (Table 1). To neutralize the IFN-
induced response, we used the inhibitor B18R, a product of vac-
cinia virus that competes with IFN for binding to the type I IFN
receptor. Based on the production of antiviral activity induced by
poIRF7/3(5D) in SK6 or IBRS-2 cells (Table 1), we used a dose of
B18R that was sufficient to neutralize up to 500 units of IFN-
without causing toxicity. Transduction of IBRS-2 cells with Ad5-
poIRF7/3(5D) completely blocked FMDV replication, and this
effect was only partially reversed by the addition of the inhibitor
B18R (Table 2). Although the antiviral activity in the supernatants
of the cells was fully neutralized by B18R (Table 3), inhibition of
FMDV replication was partially reversed (Table 2) and 46-, 448-,
and 8-fold upregulation of the IFN-, -, and - transcripts, re-
spectively (Fig. 5), was observed even in the presence of the inhib-
itor B18R combined with an anti-IFN- antibody. Even though
treatment with the inhibitor B18R in combination with anti-
IFN- markedly reduced the expression of all the ISGs tested,
several ISGs, including BST2, IFN--induced protein 10 (IP-10),
ISG56, ISG54, GBP4, MDA5, and OAS1, were upregulated to rel-
atively high levels in cells maintained with the IFN-neutralizing
treatment (Fig. 5). The fold change in transcript levels of genes
FIG 4 poIRF7/3(5D) induces an antiviral response in vitro in cells from several species. (A) Consensus tree generated using ML. Bootstrapping values are
displayed in each branch. Boxes represent the four different taxonomic groups represented in the tree. PRED, predicted, MONK, monkey. L929 (B) or MDBK
(C) cells were infected with Ad5-poIRF7/3(5D), Ad5–poIFN-, or Ad5-Blue at an MOI of 20 or mock treated with medium. At 24 h posttreatment, cells were
infected with VSV serotype New Jersey at an MOI of 1 for 24 h. Viral titers were determined by the TCID50 method. (D) BHK-21 cells were transfected with
plasmid poIRF7/3(5D) or pGFP or mock transfected with medium or were treated with poly(I·C) (100 ng/ml). At 24 h posttreatment, cells were infected with
FMDV A12 at an MOI of 0.1 for 24 h. Viral titers were determined by the TCID50 method. Statistical analysis was performed using Student’s t test. *, P 0.05.
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such as those for IP-10, OAS1, and ISG56 dropped from 8,026 to
2,235, 5,793 to 286, and 3,464 to 565, respectively. These results
suggest that poIRF7/3(5D) may stimulate genes with antiviral
function even when type I IFNs are neutralized. However, the
identity of the antiviral genes induced by poIRF7/3(5D) fully in-
dependently of IFN stimuli in a porcine system remains to be
determined.
Ad5-poIRF7/3(5D) protects mice against FMDV challenge.
It has previously been shown that high doses of FMDV cause fatal
disease in adult (6- to 7-week-old) C57BL/6 mice (45) that can be
prevented by treatment with IFN or IFN-inducing agents (42). To
determine if Ad5-poIRF7/3(5D) could induce the production of
systemic IFN and protect against FMDV challenge, we inoculated
mice with two doses (3  107 or 3  108 PFU/mouse) of Ad5-
poIRF7/3(5D) or the Ad5-Blue control.We found thatmice inoc-
ulated with the high dose (3 108 PFU/mouse) of Ad5-poIRF7/
3(5D) had statistically significantly higher levels of IFN- (P 
0.001), IFN- (P 0.05), and total induced antiviral activity (P
0.001) than those inoculated with an equivalent dose of the Ad5-
Blue control (Fig. 6A to C). Notably, Ad5-Blue induced some
antiviral activity and the production of IFN- or - when it was
used at a high dose (3  108 PFU/mouse). Mice treated with the
high dose of Ad5-poIRF7/3(5D) produced, on average, 21,195
pg/ml of IFN-, whereas 210 pg/ml was produced bymice treated
with theAd5-Blue control. Also,mice treatedwith the high dose of
Ad-poIRF7/3(5D) produced, on average, 171 pg/ml of IFN-,
whereas 85 pg/ml was produced by mice treated with the Ad5-
Blue control.
In a second experiment, groups ofmice were treated with Ad5-
poIRF7/3(5D) (3  108 PFU/mouse), Ad5-Blue (3  108 PFU/
mouse), or PBS, followed by challenge with FMDV at 6 h, 24 h, or
48 h after treatment. All mice inoculated with Ad5-poIRF7/3(5D)
were protected from FMDV challenge (Fig. 7A), none of the mice
developed viremia (Fig. 7B), and all mice had high levels of anti-
viral activity in their sera (Fig. 7C). In contrast, partial protection
was observed in the groups treated with Ad5-Blue at 6 h or 24 h
FIG5 Characterization of several type I IFNs and other geneswith antiviral functions induced byAd5-poIRF7/3(5D) in porcine cells. Analysis of gene expression
in IBRS-2 cells infected with Ad5-poIRF7/3(5D) or Ad5-Blue was performed by RT-qPCR. Relative gene expression was analyzed in cells infected with
Ad5-poIRF7/3(5D) or Ad5-Blue in the presence () or absence () of the inhibitor B18R and an anti-IFN- antibody. Mock-treated cells were used as a
reference to calculate relative gene expression using the 		CT method. IL-28R, interleukin-28 receptor.
TABLE 3 Antiviral activity of filtered supernatants of IBRS-2 cells after
treatment with Ad5-poIRF7/3(5D) in the presence or absence of IFN-
neutralizing treatmenta
Treatment
IFN concn (U/ml)
B18R and anti-IFN-
negative
B18R and anti-IFN-
positive
Ad5-poIRF7/3(5D) 11.3 0.0
Medium 0.0 0.0
Ad5-Blue 0.0 0.0
a The bioassay for antiviral activity was performed in supernatants of IBRS-2 cells
collected 24 h after infection with Ad5-poIRF7/3(5D) in the presence or absence of
IFN-neutralizing agents (B18R and anti-porcine IFN- antibody).
Porcine IRF7/3(5D) Controls FMDV Replication
October 2014 Volume 88 Number 19 jvi.asm.org 11147
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
prior to FMDV challenge (40% survival [Fig. 7A]), but all animals
in the group treated with Ad5-Blue 48 h before challenge died.
Consistent with these results, viremia was detected in the three
Ad5-Blue-inoculated groups, with the highest levels being seen in
the group inoculated 48 hprior to challenge (Fig. 7B); however, no
systemic antiviral activity was detected. All animals treated with
PBS died and developed high levels of viremia, and none of the
animals displayed any antiviral activity in their sera.
In a third experiment, groups ofmice were treatedwith 2 lower
doses of Ad5-Blue or Ad5-poIRF7/3(5D) (3  106 or 3  107
PFU/mouse) in combination with 100 IU of muIFN-, followed
by FMDV challenge (Fig. 8). We found that 100% of mice treated
with 3 107 PFU of Ad5-poIRF7/3(5D) or 3 107 PFU of Ad5-
poIRF7/3(5D) plus 100 IU muIFN- and 80% of mice treated
with 3  106 PFU of Ad5-poIRF7/3(5D) plus 100 IU muIFN-
survived FMDV challenge, developed viremia (103 to 105 PFU/
ml), and had high levels of antiviral activity in their sera (Fig. 8A to
C). In contrast, 100% mortality, high viremia (107 PFU/ml),
and antiviral activity below the levels of detectionwere found in all
groups treated with Ad5-Blue alone or in combination with 100
IUmuIFN- (Fig. 8A and B). Unexpectedly, treatment with Ad5-
poIRF7/3(5D) by itself or in combination with 100 IU muIFN-
induced similar protection. However, treatment with 100 IU of
muIFN- alone did not protect against FMDV replication, and no
animals survived the challenge.
DISCUSSION
In order to prevent or limit the spread of FMDVduring outbreaks,
it is imperative to develop methods that rapidly enhance innate
immune responses in susceptible animals. It has been shown that
overexpression of IFNs delivered with an Ad5 vector is effective in
protecting swine and cattle against different serotypes of FMDV
(25, 26, 28, 35).However, large amounts of Ad5-IFNs are required
to fully protect swine and partially protect bovines. Thus, use of
this strategy to protect large animals can be very expensive. To
circumvent this limitation, a number of strategies have been ex-
amined, including use of a combination of type I and II IFNs
which results in enhanced activity at lower doses (35), use of type
III IFN (24, 48), use of adjuvants/modulators of innate immunity
such as poly-ICLC [a synthetic complex of poly(I·C), poly-L-
lysine, and carboxymethylcellulose] (8), or use of Venezuelan
equine encephalitis replicon particles (VRPs) (42). Here, we re-
FIG 6 Inoculation with Ad5-poIRF7/3(5D) induces high levels of IFN-/ and total antiviral activity in mouse serum. Groups of mice (n
 5) were inoculated
with Ad5-poIRF7/3(5D) or Ad5-Blue at the indicated doses. muIFN- (A) ormuIFN- (B) protein levels in serumwere tested by ELISA. Values are represented
as the natural logarithm (ln) of the IFN concentration (in pg/ml). (C) Antiviral activity was measured in serum using a VSV bioassay. Values are represented as
the natural logarithm of the IFN concentration (in U/ml). Statistical analyses were performed using Student’s t test. ***, P 0.001.
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port an additional strategy that involves a fusion construct gener-
ated from porcine sequences of IRF7 and IRF3, namely, poIRF7/
3(5D). The resulting protein induced the activation of type I IFNs
and, consequently, ISGs. We demonstrate that poIRF7/3(5D) is a
powerful inducer of antiviral activity against FMDV and VSV.
Even though a small amount (25 ng) of the poIRF7/3(5D) con-
struct was transfected into porcine cells, IRF7 transcript levels
were significantly increased (Fig. 1C) and there was a significant
induction of ISGs (Fig. 1D) and antiviral activity. These results
demonstrate that even a low level of expression of this fusion
protein is sufficient to induce innate responses in porcine cells.
Importantly, the expression of this construct in vitro or in vivo did
not result in cytotoxicity at doses that drastically reduced viral
replication (6 log10 units).
Administration of an inactivated FMD vaccine or an Ad5 vec-
tor expressing the FMDV capsid requires approximately 7 days to
induce protective immunity (49, 50). As a result, vaccinated ani-
mals exposed to virus within the first 7 days after vaccination are
still susceptible to the disease (42, 51, 52). Here, we show that
administration of sufficient amounts of Ad5-poIRF7/3(5D) can
completely protectmice against FMDas early as 6 h and for at least
48 h after treatment. Furthermore, studies in vitro indicated that
inhibition of viral replication was sustained for at least 5 days
posttreatment. These results suggest that Ad5-poIRF7/3(5D)may
induce not only rapid innate immunity but also a relatively long-
lasting response that is needed for protecting animals until the
vaccine-induced adaptive immunity is effective. Moreover, our
results suggest that coadministration of Ad5-poIRF7/3(5D)might
enhance the antiviral activity of a particular IFN, such as poIFN-.
This is expected, as Ad5-poIRF7/3(5D) stimulates several sub-
types of type I IFNs, such as IFN-, -, and -, that could enhance
the antiviral properties of a single type/subtype of porcine IFN.
This information is instrumental in supporting future experi-
ments to explore if the use of Ad5-poIRF7/3(5D) will allow Ad5-
poIFN dose sparing to protect animals from FMD.
IBRS-2 cells have traditionally been used to grow FMDV in cell
culture. Apparently, high levels of viral replication are achieved in
this cell line because no induction of IFN-/mRNA is detected
(53). In this study, we confirmed that IBRS-2 cells are somewhat
impaired in their ability to induce IFN-/ compared to cells of
another porcine cell line, SK6.Unexpectedly, we detected antiviral
activity in the supernatants of IBRS-2 cells transfected with
poIRF7/3(5D), suggesting that other IFNs or IFN-independent
genes with direct antiviral activitymight have been induced by the
fusion protein.
Previous reports found that expression of IRF3 alone does not
induce the synthesis of endogenous IFN-1 and IFN- (47, 54).
However, a subset of genes was activated in cells expressing the
constitutively active form, IRF3(5D), combined with neutralizing
antibodies against IFN-/ (54). This result led us to investigate
whether poIRF7/3(5D) could induce genes with antiviral function
independently of IFN. We neutralized the antiviral activity in the
supernatants of IBRS-2 cells by combining an anti-swine IFN-
(clone K9) antibody and the inhibitor B18R, a product of vaccinia
virus that prevents the binding of type I IFN to its natural receptor
(the IFN-/ receptor) (55). The B18R protein has broad activity
FIG 7 Ad5-poIRF7/3(5D) protects mice from FMDV challenge at 6, 24, or 48 h postinoculation. Groups of mice (n
 5) were inoculated with 3 108 PFU of
Ad5-poIRF7/3(5D) or Ad5-Blue, followed by challenge with FMDVA24 (5 104 PFU/animal) at 6 h, 24 h, or 48 h. A control group was inoculated with PBS at
48 h before challenge. Animals were monitored for 7 days after challenge. (A) Survival curves; (B) FMDV titers in serum (viremia) determined by plaque assay;
(C) antiviral activity in serummeasured by VSV bioassay. *, the sera of groups inoculated with Ad5-Blue or PBS had antiviral activity below the detection levels.
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across species (56), is soluble outside the cell, and is present on the
cell surface; thus, it blocks type I IFN autocrine and paracrine
functions (55). In the presence of B18R and anti-swine IFN- at
doses that fully neutralized antiviral activity in the supernatants of
cells infected with Ad5-poIRF7/3(5D), the induction of IFN-,
-, and - transcripts was still highly upregulated. In accordance
with findings fromGrandvaux et al. (54), we found that ISG54 and
ISG56were still highly upregulated in the presence of IFNneutral-
ization treatment. The genes for other ISGs, including the GBP4
(but not GBP2), IP-10, MDA-5, Mx1, and OAS1 genes, were also
highly upregulated in the presence of the IFN neutralization treat-
ment after transduction with Ad5-poIRF7/3(5D). This is consis-
tent with the predominantly positive transcription signature de-
scribed for IRF7 (57) or a STAT1-independent mechanism of
induction, as previously reported for IP-10 during HIV infection
of astrocytes (58). A possible explanation for the high degree of
upregulation of IFN transcription in the presence of the inhibitor
B18R could be the two-step positive-feedback loop that IFN-/
employs to amplify its own expression (59, 60). While B18R in-
hibits signaling through the IFN-/ receptor (second wave), the
earlier expression of IFN- and IFN-4 (59) remains unaffected
by the use of the inhibitor B18R. Alternatively, our treatments
with B18R and anti-IFN-might not have been sufficient to neu-
tralize all subtypes of type I IFN induced by the fusion protein. The
high level of induction of IFN transcripts in the presence of IFN-
neutralizing treatment does not necessarily imply that the induc-
tion of genes with antiviral function by poIRF7/3(5D) is fully in-
dependent of IFN.
Another study using B18R to block the IFN response has
shown the induction of a lipid raft-associated protein, BST-2 (also
known as tetherin or CD317), independently of IFN. Tetherin
inhibits viral infection by preventing the diffusion of virus parti-
cles after budding from infected cells (61). Here, we confirmed
that the levels of the BST-2 transcript were induced by 16-fold in
the presence of Ad5-poIRF7/3(5D) and IFN-neutralizing treat-
ment. This antiviral protein inhibits the release of diverse envel-
oped virus particles, and it plays a role in neutralizing VSV (62).
However, a role in controlling infection of nonenveloped viruses,
such as FMDV, remains to be elucidated.
Similarly, we have also demonstrated that poIRF7/3(5D) in-
duces potent antiviral effects in cell lines of multiple species, in-
cluding bovine, hamster, and murine cell lines. In the case of mu-
rine (L929) cells, Ad5-poIRF7/3(5D) seemed to be less efficient at
reducing the viral yield, a result that was also observed when Ad5-
poIRF7/3(5D) was tested in mouse embryonic fibroblasts (data
not shown). This observation is consistent with a more distant
phylogenetic relationship between mouse and porcine sequences.
However, contrary to the case in murine cells, a reduction in the
antiviral properties of Ad5-poIRF7/3(5D) in hamster cells was not
observed. In fact, it was surprising to detect the strong antiviral
activity induced by Ad5-poIRF7/3(5D) in cell lines that have pre-
viously been reported to be defective in IFN-/ sensing or sig-
FIG 8 Efficacy studies after treatment with Ad5-poIRF7/3(5D) in combination with muIFN-. Groups of mice (n 
 5) were inoculated with Ad5-poIRF7/
3(5D), Ad5-Blue, recombinantmuIFN- protein, or combinations of these treatments at the indicated doses. Animals were challengedwith FMDVA24 (5 104
PFU/animal at 48 h after Ad5 inoculation and/or 24 h after muIFN- [100 IU] treatment). Clinical signs were monitored for 7 days. (A) Survival curve; (B)
FMDV titers in serum (viremia) determined by plaque assay; (C) antiviral activity in serum measured by a VSV inhibition bioassay. *, the sera of groups
inoculated with Ad5-Blue or PBS had antiviral activity below the detection levels.
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naling (63, 64) and that are routinely used for viral expansion and
production of FMD vaccines (65). BHK-21 cells did not respond
to poly(I·C) stimulation (or viral infection) but responded to
treatment with the poIRF7/3(5D) protein, suggesting that expres-
sion of this protein bypasses certain limitations in antiviral path-
ways. Treatment with poIRF7/3(5D) in BHK-21 or IBRS-2 cells
might bypass a defect in pathogen-associated molecular pattern
(PAMP) sensing or transduction pathways and directly induce
strong transcription of IFN or other genes with antiviral activities.
Further studies are required to characterize the plethora of re-
sponses that could be induced by the fusion protein in these cell
lines.
Characterization of the antiviral activity induced by poIRF7/
3(5D) in porcine cells led us to identify type I IFNs but not type III
IFN (IFN-3 or IL-28B) as major players in the induced antiviral
effect. Type III IFN includes three IFN-molecules (IFN-1, -2,
and -3, which are also known as IL-29, IL-28A, and IL-28B, re-
spectively) (39). These cytokines induce innate antiviral responses
similar to those induced by type I IFNs, but they have different
structures and bind a different cell surface receptor (9, 24). Con-
trary to our findings using poIRF7/3(5D) in porcine cells, it has
been reported that human IFN-2/3 gene expression is mainly
controlled by IRF7 (66). In accordance with our results, another
study suggested that type III IFNs are induced through indepen-
dent actions of IRFs and nuclear factor kappa B (NF-B) (67).
Another report also suggested that the c-REL/p65 NF-B het-
erodimer and IRF1 are the main transcriptional regulators of type
III IFNs (68). Further studies are needed to study the regulation of
type III IFN in porcine cells.
We found that expression of poIRF7/3(5D) induced the ex-
pression of various but not all type I IFN mRNAs, including
IFN-, -, or -mRNA.We are currently working to identify the
subtypes of IFN type I with higher antiviral activity during FMDV
infection in the presence and absence of the Ad5-poIRF7/3(5D)
stimulation. These results are consistent with previous reports in
which IFN-ε was mainly associated with cells of reproductive
function and IFN- expressed in epidermal keratinocytes (69).
IFN- has been shown to have high levels of antiviral activity in
porcine cells and a relevant biological role during early pregnancy
when it is secreted by the trophectodermof the pig conceptus (70).
Finally, the results obtained in vitro prompted us to evaluate
the effectiveness of poIRF7/3(5D) in protectingmice from FMDV
infection. We found that mice challenged with FMDV A24 at 6,
24, or 48 h postinoculationwithAd5-poIRF7/3(5D) fully survived
viral challenge and did not develop viremia. To evaluate if expres-
sion of the chimeric protein poIRF7/3(5D) could potentially allow
sparing of the amount of Ad5-IFN required to induce protection,
we also performed experiments in mice. Since poIFN- is not
active in themurine system, we combined recombinantmuIFN-
at a dose known not to be protective by itself (100 IU/animal) with
Ad5-poIRF7/3(5D). Unfortunately, we could not detect an en-
hancement of the antiviral activity in the sera of the treated ani-
mals or an increase in the rate of survival after inoculation with
the combination treatment. Presumably, the antiviral activity of
muIFN- protein decayed rapidly after administration. Even
though further standardization of the dose of type I IFN is re-
quired to demonstrate potentiation between IFN and Ad5-
poIRF7/3(5D), here we report that low doses (3  106 PFU/
mouse) of Ad5-poIRF7/3(5D) fully or partially protected mice
from FMDV challenge. These findings support future work in
which the potentiation ability of Ad5-poIFNs and Ad5-poIRF7/
3(5D) will be assessed using swine.
Confirming the results from our in vitro studies, mice treated
with Ad5-poIRF7/3(5D) at a high dose (3  108 PFU/mouse)
produced on average of 100 times more IFN- than the control
group. Ad5-poIRF7/3(5D) at a high dose also induced the upregu-
lation of IFN- to a lesser extent than it induced the upregulation
of IFN-. These results are consistent with the rapid antiviral ac-
tivity detected in mouse sera at 24 hpt. In contrast, IFN- tran-
scripts were induced at approximately 10-fold higher levels than
IFN- transcripts in cultured epithelial porcine cells infected with
Ad5-poIRF7/3(5D). Nevertheless, when IFN- transcripts were
highly upregulated in vitro, antiviral activity accounted for only
less than 10% after neutralization with IFN--specific antibodies.
Further analysis of IFN transcripts and protein from in vivo exper-
iments using porcine tissues and serum is necessary to make a
more relevant comparison.
Altogether, our results demonstrate that poIRF7/3(5D) is a
robust inducer of innate immunity in porcine cells. Furthermore,
poIRF7/3(5D) inhibits viral replication in cell lines from several
species, including porcine, murine, and bovine cell lines, suggest-
ing that a single poIRF7/3(5D) constructmight hold biotherapeu-
tic properties across species of interest, thus potentially inducing
protection against FMDV, a virus that affects a wide range of live-
stock and more than 70 species of wildlife. A more precise under-
standing of the role of poIRF7/3(5D) in blocking FMDV replica-
tion in vivo will come from future studies in the natural host.
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